This case highlights that some individuals may respond very differently to tirzepatide compared to semaglutide, even when the medications share similar mechanisms
Week 12 and Beyond: Maintenance In the long-term maintenance phase, patients maintain a consistent weekly dose
This approval framework reflects the current medical understanding that obesity is a chronic, relapsing disease requiring long-term pharmacological intervention in many patients
This has nothing to do with b12 status and everything to do with excessive caloric deficit and insufficient protein intake relative to the rate of weight change
This includes coverage of medical bills, lost wages, and pain and suffering
[109] Others, including Natco Pharma ( Semanat and Semafull ) [110] and Mankind Pharma [111] also planned product launches around the same time, and in total, 4050 total brands of semaglutide were expected to become available in India in the following months